Clinical trials: Stable Renal Recipients
Transplant Rejection, Renal Transplantation
Study To Evaluate Pharmacokinetics Of Sirolimus In Stable Renal Transplant Recipients
Sirolimus, 1 mg, white, triangular tablets (Rapamune®) was approved on 03 April 2007 in China for prophylaxis of organ rejection in renal transplantation.
- Trial name
- NCT01236378
- Testing
- Sirolimus
- Where
- 2 sites in China
- Volunteers
- 24 people
- Sponsor
- Pfizer
Kidney Transplantation
Pharmacokinetic Profile of Myfortic in Combination With Tacrolimus in Fed Versus Fasting State
Literature regarding the effect of food on the pharmacokinetic (PK) profile of enteric-coated mycophenolate sodium combined with tacrolimus and corticosteroid withdrawal is lacking.
- Trial name
- NCT00585468
- Testing
- Myfortic
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Utah
Renal Transplantation, Kidney Transplantation
A Single Center, Open-label, Randomized, Pilot Study to Evaluate the Safety and Efficacy of a Tacrolimus Modified Release, ADVAGRAF®, Versus Tacrolimus Twice Daily, PROGRAF® in Stable Renal Recipients
The purpose of this study is to evaluate and compare the safety and efficacy of two drugs (ADVAGRAF® and PROGRAF® groups) in patients who received renal transplantation.
- Conditions
- Renal Transplantation, Kidney Transplantation, Stable Renal Recipients
- Trial name
- SINGLE (NCT01742676)
- Testing
- ADVAGRAF, PROGRAF
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Astellas Pharma Korea, Inc.
Kidney Diseases
Steroid Withdrawal in Pediatric Renal Transplant Recipients Under Cyclosporine (CyA) and Mycophenolate Mofetil (MMF)
The present study investigates the safety and efficacy of steroid withdrawal in pediatric renal transplant recipients with stable graft function under concomitant immunosuppression with cyclosporine and mycophenolate mofetil.
- Trial name
- NCT00309218
- Testing
- methylprednisolone
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- Klinik für Kinder- und Jugendmedizin
Chronic Allograft Nephropathy
Calcineurin Inhibitor Minimisation in Renal Transplant Recipients With Stable Allograft Function
The purpose of this trial is to ascertain whether the withdrawal of calcineurin inhibitors (CNI) will lead to less kidney transplant damage when compared with minimisation.
- Trial name
- CNIM-SRT (NCT00541814)
- Testing
- Cyclosporine
- Where
- United Kingdom
- Volunteers
- 90 people
- Sponsor
- University Hospital Birmingham
Renal Transplantation
Study Evaluating Conversion From Tacrolimus to Sirolimus in Stable Kidney Transplant Recipients Receiving Myfortic
The purpose of this study is to determine whether the combination of Myfortic and sirolimus is effective at preventing rejection while preserving kidney function in stable kidney transplant recipients.
- Trial name
- MYFIIRP (NCT00713284)
- Testing
- sirolimus
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- California Pacific Medical Center Research Institute
Renal Transplantation
Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.
Calcineurin inhibitors (CNI), a potent immunosuppressive drug used in kidney transplant recipients to prevent graft rejection, may cause renal impairment.
- Trial name
- NCT00332839
- Testing
- Everolimus, Cyclosporin A (CsA), Tacrolimus
- Where
- 11 sites in Germany
- Volunteers
- 93 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Diseases
Enteric-coated Mycophenolate Sodium (EC-MPS) With Reduced-dose Tacrolimus Versus EC-MPS With Standard-dose Tacrolimus in Stable Kidney Transplant Recipients
This study introduces a new optimization immunosuppressive regimen associating tacrolimus at a reduced dose and enteric-coated mycophenolate sodium at an increased dose in order to slow down renal function worsening and to…
- Trial name
- OLYMPE (NCT00284934)
- Testing
- Enteric-coated mycophenolate sodium (EC-MPS), Tacrolimus, Corticosteroids
- Where
- Switzerland
- Volunteers
- 94 people
- Sponsor
- Novartis
Transplantation
A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Kidney Recipients
Assessment of the safety and the efficacy of a tacrolimus modified release (MR4) based immunosuppressive regimen in stable kidney transplant subjects converted on a 1:1 (mg:mg) basis from a Prograf® based immunosuppressive…
- Trial name
- NCT00384137
- Testing
- Tacrolimus
- Where
- 13 sites in France, Germany and 4 more
- Volunteers
- 128 people
- Sponsor
- Astellas Pharma Inc
Renal Disease, Renal Transplant
Comparison of Medication Adherence Between Once and Twice Daily Tacrolimus in Stable Renal Transplant Recipients
A critical aspect of real-world functioning following kidney transplantation involves how adherent individuals are to their medication regimens.
- Trial name
- NCT01334333
- Testing
- Tacrolimus - Prograf® twice daily formulation, Tacrolimus - Advagraf® once daily formulation
- Where
- Canada
- Volunteers
- 46 people
- Sponsor
- University of British Columbia
Transplant; Failure, Kidney, Hypertension
The Impact of Nebivolol Versus Metoprolol on Quality of Life
In an open label analysis, nebivolol has been shown to have a positive impact on quality of life in the general hypertensive population.
- Trial name
- NCT01441570
- Testing
- Nebivolol, Metoprolol succinate
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Brigham and Women's Hospital
Cardiac Output, Low, High Blood Pressure
Assessment of Volumetric Hemodynamic Parameters and Nutritional Status in Stable Renal Transplant Recipients
Changes in volumetric hemodynamic parameters and fluid overload (Cardiac Index,Stroke Volume, Thoracic Fluid Content, Systemic Vascular Resistance) were measured using a impedance cardiography (ICG) (CardioScreen 1000 …
- Trial name
- NCT02852941
- Testing
- CardioScreen 1000, Tanita 418- Bioelectrical impedance analysis
- Where
- Poland
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Medical University of Warsaw